ICO Monograph Series on HPV and Cervical Cancer: Asia Pacific Regional ReportHuman Papillomavirus and Cervical Cancer in Australasia and Oceania: Risk-factors, Epidemiology and Prevention
Introduction
The region encompassing Australasia (Australia and New Zealand) and Oceania is culturally, ethnically, and economically diverse, which influences the availability of high quality health care systems. Countries in the region vary from those with well-organised cervical cancer screening programmes with high coverage, as well as government funded universal human papillomavirus (HPV) vaccine programmes, to those countries with no cervical cancer screening or planned vaccine initiatives. This review aims to describe the level of morbidity due to cervical cancer within countries in the region. We describe the various initiatives taken by these countries in cervical cancer prevention, their achievements, but also the huge scope for improvement. In describing deployment of the HPV vaccine, we provide considerable detail as to how this is occurring in Australia, as this was the first country to implement a universal female HPV vaccination initiative and may be a model for others.
Section snippets
Cervical cancer incidence and mortality across Australasia and Oceania
In Australia and New Zealand (NZ), the introduction of national cervical screening programmes of high quality, wide coverage, as well as adequate treatment for precancerous lesions, has resulted in significant reductions in cervical cancer incidence, as well as mortality. This is in marked contrast to other countries in the region (e.g., Fiji and Papua New Guinea (PNG)) that have some of the highest rates of cervical cancer in the world, with late presentations and concomitant high morbidity
Co-factors for HPV exposure and carcinogenesis
The most comprehensive source of data on sexual behaviour at the population level is from the Australian Study of Health and Relationships (ASHR) in 2002 of 19,307 Australians aged 16–59 years, which had a response rate of 73% [8], [9]. The mean number of lifetime sexual partners varied by age (Table 1). Of the men surveyed between the ages of 16 and 24, 22% reported more than one sexual partner in the previous year and the equivalent figure for women was 14%. For those aged 25–34 years, 15% of
Australia
In Australia, the National Cervical Screening Programme, using conventional Pap testing starts at age 18 or two years after sexual debut, whichever is later and continues at two-year intervals until age 69. The programme achieves coverage of approximately 61% at the two year screening interval and approximately 80% at three years [1].
Laboratory quality is actively regulated through a system of performance measures and laboratory accreditation, linked to ongoing funding. The implementation of
Australia
New vaccines are initially assessed by the Therapeutic Goods Administration (TGA) for listing on the Australian register of Therapeutic Goods. Advice to the government about the possible role of the vaccine in the Australian population is provided by the Australian Technical Advisory Group on Immunisation (ATAGI). Since 2006, ATAGI also provides advice to the Pharmaceutical Benefits Advisory Committee (PBAC), whose role is to make recommendations to the government regarding public funding of
Conclusion and Research needs
Within this region there is an extreme disparity in preventive service provision by country and this is reflected in the levels of disparity in cervical cancer screening programmes from very effective to nonexistent. There is commensurate variation in cervical cancer incidence and mortality. Unfortunately many countries in the region have the highest mortality due to cervical cancer in the world, while accurate cervical cancer incidence data in many instances is inadequate. There is a need to
References (53)
- et al.
Cancer incidence and survival for indigenous Australians in the Northern Territory
Aust N Z J Public Health
(2005) - et al.
Sex in Australia: selected characteristics of regular sexual relationships
Aust N Z J Public Health
(2003) - et al.
Sex in Australia: First experiences of vaginal intercourse and oral sex among a representative sample of adults
Aust N Z J Public Health
(2003) How much cervical cancer in Australia is vaccine preventable? A meta-analysis
Vaccine
(2008)- et al.
Randomised controlled trial of an educational strategy to increase school-based adolescent hepatitis B vaccination
Aust N Z J Public Health
(2000) - et al.
A cross-sectional survey to assess community attitudes to introduction of Human Papillomavirus vaccine
Aust N Z J Public Health
(2007) - et al.
HPV vaccination: what do Queensland parents think?
Aust N Z J Public Health
(2007) - Australian Institute of Health and Welfare. Cervical Screening in Australia 2004–2005. Cancer series No. 38. Canberra:...
- Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al. Cancer Incidence in Five Continents. Vol. I to XI....
- et al.
Disparities in indigenous health: a cross-country comparison between New Zealand and the United States
Am J Public Health
(2005)
Global Cancer Statistics, 2002
CA Cancer J Clin
Chapter 1: HPV in the etiology of human cancer
Vaccine
National Notifiable Diseases Surveillance System: Notifications of a selected disease by age group, sex and year
Aust Government Dept Health Aging
Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis
Br J Cancer
Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia
Int J Gynecol Cancer
Human papillomavirus genotypes and their association with cervical neoplasia in a cohort of Western Australian women
J Med Virol
Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results
J Clin Microbiol
Population seroprevalence to human papillomavirus types 6, 11, 16, and 18 in men, women and children in Australia
Clin Infect Dis
A health profile of New Zealand youth who attend secondary school
NZ Med J
Contraceptive use by Maori youth in New Zealand: associated risk and protective factors
NZ Med J
Cited by (54)
Prevention of cervical cancer: Journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine
2016, Current Opinion in Chemical BiologyA qualitative study investigating knowledge and attitudes regarding human papillomavirus (HPV) and the HPV vaccine among parents of immunosuppressed children
2012, VaccineCitation Excerpt :The vaccines are registered for use in Australia in females aged 9–26 years and in males aged 9–15 years (the latter registration is based on immunogenicity and safety data alone, rather than efficacy data). To date, the HPV vaccine has only been funded for 12–13 year old girls in the first year of secondary school [6], with a recent decision to commence a funded program for boys commencing in 2013 in Australia [7]. When the vaccine was first introduced, a catch-up program that consisted of two components (a school-based program and a community-based program) was instituted.